HC Wainwright & Co. Maintains Allogene Therapeutics (ALLO) Buy Recommendation

On April 4, 2023,
HC Wainwright & Co.
maintained
coverage of Allogene Therapeutics with
a Buy recommendation.

Analyst Price Forecast Suggests 294.83% Upside

As of March 30, 2023,
the average one-year price target for Allogene Therapeutics is $19.19.
The forecasts range from a low of $6.06 to a high of $36.75.
The average price target represents an increase of 294.83% from its latest reported closing price of $4.86.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Allogene Therapeutics
is $4MM, an increase of 1,539.92%.

The projected annual non-GAAP EPS
is -$2.83.

What are Other Shareholders Doing?

Nisa Investment Advisors
holds 1K shares

representing 0.00% ownership of the company.

In it’s prior filing, the firm reported owning 1K shares, representing
a decrease
of 12.14%.

The firm

decreased

its portfolio allocation in ALLO by 38.21% over the last quarter.

California State Teachers Retirement System
holds 107K shares

representing 0.07% ownership of the company.

In it’s prior filing, the firm reported owning 106K shares, representing
an increase
of 1.09%.

The firm

decreased

its portfolio allocation in ALLO by 45.27% over the last quarter.

RMB Capital Management
holds 29K shares

representing 0.02% ownership of the company.

In it’s prior filing, the firm reported owning 18K shares, representing
an increase
of 37.10%.

The firm

decreased

its portfolio allocation in ALLO by 12.81% over the last quarter.

FLXSX – Fidelity Flex Small Cap Index Fund
holds 9K shares

representing 0.01% ownership of the company.

In it’s prior filing, the firm reported owning 9K shares, representing
an increase
of 7.49%.

The firm

decreased

its portfolio allocation in ALLO by 26.36% over the last quarter.

FCFMX – Fidelity Series Total Market Index Fund
holds 109K shares

representing 0.08% ownership of the company.

In it’s prior filing, the firm reported owning 86K shares, representing
an increase
of 21.06%.

The firm

decreased

its portfolio allocation in ALLO by 12.27% over the last quarter.

What is the Fund Sentiment?

There are 391 funds or institutions reporting positions in Allogene Therapeutics.

This is a decrease
of
36
owner(s) or 8.43% in the last quarter.

Average portfolio weight of all funds dedicated to ALLO is 0.14%,
a decrease
of 17.31%.

Total shares owned by institutions increased
in the last three months by 3.62% to 125,183K shares.

The put/call ratio of ALLO is 2.70, indicating a

bearish
outlook.

Allogene Therapeutics Background Information
(This description is provided by the company.)

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of ‘off-the-shelf’ CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

See all Allogene Therapeutics regulatory filings.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.